 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2020264.3403
Published online: 29 October 2020
Original article
J of IMAB. 2020 Oct-Dec;26(4):3403-3407
IDENTIFICATION AND QUANTIFICATION OF VERAPAMIL IN BLOOD AND URINE
Georgi Bonchev1
, Snezha Zlateva1, 2, Petko Marinov1, 2, Ivelina Stefanova1,
1) Clinic for Intensive Treatment of Acute Intoxications and Toxicoallergies, Naval Hospital – Varna, Military Medical Academy, Bulgaria
2) Department of Pharmacology, Toxicology and Pharmacotherapy, Faculty of Pharmacy, Medical University - Varna, Bulgaria.
ABSTRACT:
Purpose: To adapt and validate an HPLC method for verapamil determination in blood and urine samples.
Materials/Methods: Identification of verapamil and its metabolites was made by means of gas-chromatography, using Agilent 7890B/5977A GC-MS system featuring a DB-1701 column. Quantification was done by means of liquid chromatography on Agilent 1260 series HPLC, equipped with Zorbax Extend-C18 column and both diode-array and fluorescent detection modules. Blood and urine specimens were taken from patients of the Clinic for intensive treatment of acute intoxications and toxicoallergies within the course of their treatment.
Results: GC-MS identification of verapamil and its metabolites was carried out after simple liquid-liquid extraction of samples without further chemical derivatization. Adapted HPLC method for quantification require isocratic conditions and mobile phase, consisted of phosphate buffer (pH 2.7; 10 mM) containing 1.5 ml L–1 triethylamine – acetonitrile (70:30, v/v) at 20oC, flow-rate 1.0 mL/min and FLD detection (excitation: 203 nm, emission: 320 nm). The method was demonstrated to be linear within the whole region of interest (4.6-4600 ng mL–1) with excellent accuracy (101.7-102.2%) and inter-day precision (5.81%) as well as good analytical recovery (81.2%) and LOQ (7.0 ng mL–1).
Conclusion: A precise and easy to use method for verapamil detection and quantification is developed. The method is applicable as a routine procedure in the Laboratory of analytical toxicology for both diagnosis clarification in cases of acute intoxications and therapeutic drug monitoring.
Keywords: verapamil, GC-MS, HPLC, acute intoxications, therapeutic drug monitoring,
- Download FULL TEXT /PDF 496 KB/
Please cite this article as: Bonchev G, Zlateva S, Marinov P, Stefanova I. Identification and quantification of verapamil in blood and urine. J of IMAB. 2020 Oct-Dec;26(4):3403-3407.
DOI: 10.5272/jimab.2020264.3403
Correspondence to: Georgi Bonchev, PhD., Head, Laboratory of Analytical Toxicology, Military Medical Academy, Naval Hospital – Varna; 3, Chr. Smirnenski St, Varna – 9010, Bulgaria; E-mail: toxilab.varna@abv.bg
REFERENCES:
1. Lewis GR, Morley KD, Lewis BM, Bones PJ. The treatment of hypertension with verapamil. N Z Med J. 1978 May 24;87(612):351-4. [PubMed]
2. Anavekar SN, Christophidis N, Louis WJ, Doyle AE. Verapamil in the treatment of hypertension. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):287-92. [PubMed]
3. Frishman WH, Charlap S. Verapamil in treatment of chronic stable angina. Arch Intern Med. 1983 Jul;143(7):1407-15. [PubMed]
4. Krikler DM, Spurrell RA. Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad Med J. 1974 Jul;50(585):447-53. [PubMed]
5. Giannini AJ, Houser WL Jr, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. Am J Psychiatry. 1984 Dec;141(12):1602-3. [PubMed]
6. Giannini AJ, Taraszewski R, Loiselle RH. Verapamil and lithium in maintenance therapy of manic patients. J Clin Pharmacol. 1987 Dec;27(12):980-2. [PubMed]
7. Alabdulrazzaq F, Koren G. Fetal safety of calcium channel blockers. Can Fam Physician. 2012 Jul;58(7):746-7. [PubMed]
8. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012 Jul 26;16(4):R136. [PubMed]
9. Speders S, Sosna J, Schumacher A, Pfennigsdorf G. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol. 1989;13 Suppl 4:S47-9. [PubMed]
10. Immonen P, Linkola A, Waris E. Three cases of severe verapamil poisoning. Int J Cardiol. 1981;1(1):101-5. [PubMed]
11. Pritza DR, Bierman MH, Hammeke MD. Acute toxic effects of sustained-release verapamil in chronic renal failure. Arch Intern Med. 1991 Oct;151(10):2081-4. [PubMed]
12. Ashraf M, Chaudhary K, Nelson J, Thompson W. Massive overdose of sustained-release verapamil: a case report and review of literature. Am J Med Sci. 1995 Dec;310(6):258-63. [PubMed]
13. Klimaszyk D. [ECG disorders in the course of acute suicidal poisonings by verapamil]. [in Polish] Przegl Lek. 2000; 57(10):600-5. [PubMed]
14. Nickson CP, Little M. Early use of high-dose insulin euglycaemic therapy for verapamil toxicity. Med J Aust. 2009 Sep 21;191(6):350-2. [PubMed]
15. Osthoff M, Bernsmeier C, Marsch SC, Hunziker PR. Levosimendan as treatment option in severe verapamil intoxication: a case report and review of the literature. Case Rep Med. 2010; 2010.pii:546904. [PubMed]
16. Izdes S, Altintas ND, Soykut C. Acute respiratory distress syndrome after verapamil intoxication: case report and literature review. Acta Clin Belg. 2014 Apr;69(2):116-9. [PubMed]
17. Liang CW, Diamond SJ, Hagg DS. Lipid rescue of massive verapamil overdose: a case report. J Med Case Rep. 2011 Aug 20;5:399. [PubMed]
18. Sampson CS, Bedy SM. Lipid emulsion therapy given intraosseously in massive verapamil overdose. Am J Emerg Med. 2015 Dec;33(12):1844.e1. [PubMed]
19. Mandigers L, Bollen PD, Bijlstra PJ, Brands E. Severe verapamil intoxication despite correct use of low-dose verapamil. Drug Metab Pers Ther. 2016 Mar;31(1):55-8. [PubMed]
20. Tulgar S, Kose HC, Demir Piroglu I, Karakilic E, Ates NG, Demir A, et al. Comparison of effects of separate and combined sugammadex and lipid emulsion administration on hemodynamic parameters and survival in a rat model of verapamil toxicity. Med Sci Monit. 2016 Mar 25;22:984-90. [PubMed]
21. Şahin FA, Çelebi SH, Güngör I, Coşkun D, Kaya ;EE. Therapeutic effects of intralipid and medialipid emulsionsin a rat model of verapamil toxicity. Turk J Med Sci. 2016 Nov 17;46(5):1568-1572. [PubMed]
22. DRUGBANK: Verapamil. [Retrieved 2019 Jul 10] [Internet]
23. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol. 1999 May;47(5):545-52. [PubMed]
24. Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos. 2003 Jul;31(7):888-91. [PubMed]
25. Walles M, Thum T, Levsen K, Borlak J. Metabolism of verapamil: 24 new phase I and phase II metabolites identified in cell cultures of rat hepatocytes by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Dec 25;798(2):265-74. [PubMed]
26. Charpentier C, Flandrois M, Labombarda F, Maragnes P, Jokic M, Villedieu F. [Verapamil intoxication: beware of the delayed effect]. [in French] Arch Pediatr. 2014 Dec;21(12):1344-7. [PubMed]
27. Thomson BM, Pannell LK. The analysis of verapamil in postmortem specimens by HPLC and GC. J Anal Toxicol. 1981 May-Jun;5(3):105-9. [PubMed]
28. Bhatia NM, Pathade PA, More HN, Choudhari PB, Jadhav SD, Bhatia MS, et al. Synthesis and characterization of norverapamil and quantification of verapamil and nor-verapamil in plasma. J Anal Chem. 2013 Oct;68(10):924-30. [Crossref]
29. Hynning PA, Anderson P, Bondesson U, Boreus LO. Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. Clin Chem. 1988 Dec;34(12):2502-3. [PubMed]
30. Ellenhorn MJ. Ellenhorn’s Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Schonwald SN, Ordog G, Wasserberger J. (Eds.) Williams & Wilkins. Subsequent edition. January 1, 1997. 534 p.
31. Sawicki W. A validated method for the determination of verapamil and norverapamil in human plasma. J Pharm Biomed Anal. 2001 Jun;25(3-4):689-95. [PubMed]
32. Chytil L, Strauch B, Cvacka J, Maresova V, Widimsky J Jr, Holaj R, et al. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3167-73. [PubMed]
33. Yazan Y, Bozan B. Rapid analysis of verapamil in plasma by reversed phase HPLC. Pharmazie. 1995 Feb;50(2):117-9. [PubMed]
34. Ivanova V, Zendelovska D, Stefova M, Stafilov T. HPLC method for determination of verapamil in human plasma after solid-phase extraction. J Biochem Biophys Methods. 2008 Apr 24;70(6):1297-303. [PubMed].
Received: 16 July 2019
Published online: 29 October 2020